Galantamine
- Atc Codes:N06DA04
- CAS Codes:1953-04-4
- PHARMGKB ID:1953-04-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Galafix, Galafont, Galamil, Galantamin, Galatifer, Reminyl; Belgium: Reminyl; Bulgaria: Nivalin; Cyprus: Reminyl; Czech Republic: Apo-Galant, Galantamin, Reminyl; Denmark: Reminyl; Estonia: Reminyl; Finland: Reminyl; France: Reminyl; Germany: Reminyl; Greece: Aneprosil, Galantamine, Galantaprol, Galanthine, Memo-Farmellas, Memoton Life, Reminyl; Ireland: Galantamine, Reminyl; Italy: Reminyl; Latvia: Nivalin; Malta: Reminyl; Netherlands: Reminyl; Poland: Nivalin, Reminyl; Portugal: Galantamina, Reminyl; Romania: Reminyl; Spain: Reminyl; Slovakia: Galantamin, Reminyl; Slovenia: Galantamin, Reminyl; Sweden: Reminyl; UK: Reminyl.
North America
Canada: Reminyl; USA: Razadyne.
Latin America
Argentina: Intelec, Numencial, Reminyl; Brazil: Reminyl; Mexico: Reminyl.
Drug combinations
Chemistry
Galantamine Hydrobromide: C~17~H~21~NO~3~ HBr. Mw: 368.27. (1) 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4aS,6R,8aS)-; (2)(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide. CAS-1953-04-4 (2000).
Pharmacologic Category
Parasympathomimetic (Cholinergic) Agents; Central Acetylcholinesterase Inhibitor. Anti-Dementia Agents; Cholinesterase Inhibitors. (ATC-Code: N06DA04).
Mechanism of action
Centrally-acting cholinesterase inhibitor (competitive and reversible). Elevates acetylcholine in cerebral cortex by slowing degradation of acetylcholine. Modulates nicotinic acetylcholine receptor to increase acetylcholine from surviving presynaptic nerve terminals. May increase glutamate and serotonin levels.
Therapeutic use
Palliative treatment of mild to moderate Alzheimer’s-type dementia.
Pregnancy and lactiation implications
There are no well-controlled studies in pregnant women. Should be used in pregnancy only if benefit outweighs potential risk to fetus.
Unlabeled use
Severe dementia associated with Alzheimer’s disease. Mild-to-moderate dementia associated with Parkinson’s disease. Lewy body dementia.
Contraindications
Hypersensitivity to galantamine or any component of the formulation. Severe liver dysfunction. Severe renal dysfunction (CrCl <9 mL/minute).
Warnings and precautions
May cause anorexia, weight loss, diarrhea, nausea, or vomiting. Might cause bradycardia and/or heart block (vagotonic effects). Use with caution in sick-sinus syndrome, bradycardia, or conduction abnormalities. Use with caution in mild to moderate liver impairment (not recommended in severe impairment), moderate renal impairment (not recommended in severe impairment (CrCl <9 mL/minute)), chronic obstructive pulmonary disease and/or asthma, history of seizure disorder, bladder outlet obstruction or prostatic hyperplasia (may cause or worsen outflow obstructions, including possible exacerbation of benign prostatic hypertrophy symptoms). May increase gastric acid secretion (use with caution in risk patients, e.g. previous history of NSAID use). May exaggerate neuromuscular blockade effects of depolarizing neuromuscular-blocking agents such as succinylcholine.